These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 31720294)

  • 1. Behavioural interventions targeting physical activity improve psychocognitive outcomes in COPD.
    Lavoie KL; Sedeno M; Hamilton A; Li PZ; De Sousa D; Troosters T; Maltais F; Bourbeau J
    ERJ Open Res; 2019 Oct; 5(4):. PubMed ID: 31720294
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Bronchodilation, Exercise Training, and Behavior Modification on Symptoms and Physical Activity in Chronic Obstructive Pulmonary Disease.
    Troosters T; Maltais F; Leidy N; Lavoie KL; Sedeno M; Janssens W; Garcia-Aymerich J; Erzen D; De Sousa D; Korducki L; Hamilton A; Bourbeau J
    Am J Respir Crit Care Med; 2018 Oct; 198(8):1021-1032. PubMed ID: 29664681
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms associated with increased physical activity in patients undergoing self-management behaviour modification in the randomised PHYSACTO trial.
    Bourbeau J; Sedeno M; Li PZ; Troosters T; Hamilton A; De Sousa D; Maltais F; Erzen D; Lavoie KL
    ERJ Open Res; 2021 Jan; 7(1):. PubMed ID: 33816600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhancing exercise tolerance and physical activity in COPD with combined pharmacological and non-pharmacological interventions: PHYSACTO randomised, placebo-controlled study design.
    Troosters T; Bourbeau J; Maltais F; Leidy N; Erzen D; De Sousa D; Korducki L; Hamilton A
    BMJ Open; 2016 Apr; 6(4):e010106. PubMed ID: 27075841
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Behaviour-change intervention in a multicentre, randomised, placebo-controlled COPD study: methodological considerations and implementation.
    Bourbeau J; Lavoie KL; Sedeno M; De Sousa D; Erzen D; Hamilton A; Maltais F; Troosters T; Leidy N
    BMJ Open; 2016 Apr; 6(4):e010109. PubMed ID: 27044576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of Tiotropium/Olodaterol Compared with Tiotropium as a First-Line Maintenance Treatment in Patients with COPD Who Are Naïve to LAMA, LABA and ICS: Pooled Analysis of Four Clinical Trials.
    Buhl R; de la Hoz A; Xue W; Singh D; Ferguson GT
    Adv Ther; 2020 Oct; 37(10):4175-4189. PubMed ID: 32671684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of combined tiotropium/olodaterol on inspiratory capacity and exercise endurance in COPD.
    O'Donnell DE; Casaburi R; Frith P; Kirsten A; De Sousa D; Hamilton A; Xue W; Maltais F
    Eur Respir J; 2017 Apr; 49(4):. PubMed ID: 28424359
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of tiotropium and olodaterol on symptoms and patient-reported outcomes in patients with COPD: results from four randomised, double-blind studies.
    Ferguson GT; Karpel J; Bennett N; Clerisme-Beaty E; Grönke L; Voß F; Buhl R
    NPJ Prim Care Respir Med; 2017 Feb; 27(1):7. PubMed ID: 28154373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of Tiotropium/Olodaterol on Activity-Related Breathlessness, Exercise Endurance and Physical Activity in Patients with COPD: Narrative Review with Meta-/Pooled Analyses.
    Maltais F; de la Hoz A; Casaburi R; O'Donnell D
    Adv Ther; 2021 Feb; 38(2):835-853. PubMed ID: 33306188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Study Design of VESUTO
    Ichinose M; Minakata Y; Motegi T; Ueki J; Seki T; Anzai T; Takizawa A; Grönke L; Hirata K
    Adv Ther; 2017 Jul; 34(7):1622-1635. PubMed ID: 28537001
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Behavioural modification interventions for medically unexplained symptoms in primary care: systematic reviews and economic evaluation.
    Leaviss J; Davis S; Ren S; Hamilton J; Scope A; Booth A; Sutton A; Parry G; Buszewicz M; Moss-Morris R; White P
    Health Technol Assess; 2020 Sep; 24(46):1-490. PubMed ID: 32975190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive pulmonary disease.
    Farne HA; Cates CJ
    Cochrane Database Syst Rev; 2015 Oct; (10):CD008989. PubMed ID: 26490945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improvement In Self-Reported Physical Functioning With Tiotropium/Olodaterol In Central And Eastern European COPD Patients.
    Valipour A; Tamm M; Kociánová J; Bayer V; Sanzharovskaya M; Medvedchikov A; Haaksma-Herczegh M; Mucsi J; Fridlender Z; Toma C; Belevskiy A; Matula B; Šorli J
    Int J Chron Obstruct Pulmon Dis; 2019; 14():2343-2354. PubMed ID: 31632003
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD.
    Keam SJ; Keating GM
    Treat Respir Med; 2004; 3(4):247-68. PubMed ID: 15350163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The once-daily fixed-dose combination of olodaterol and tiotropium in the management of COPD: current evidence and future prospects.
    Derom E; Brusselle GG; Joos GF
    Ther Adv Respir Dis; 2019; 13():1753466619843426. PubMed ID: 31002020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of 12 weeks of once-daily tiotropium/olodaterol on exercise endurance during constant work-rate cycling and endurance shuttle walking in chronic obstructive pulmonary disease.
    Maltais F; O'Donnell D; Gáldiz Iturri JB; Kirsten AM; Singh D; Hamilton A; Tetzlaff K; Zhao Y; Casaburi R
    Ther Adv Respir Dis; 2018; 12():1753465818755091. PubMed ID: 29439648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of nebulized formoterol as add-on therapy in COPD patients receiving maintenance tiotropium bromide: Results from a 6-week, randomized, placebo-controlled, clinical trial.
    Hanania NA; Boota A; Kerwin E; Tomlinson L; Denis-Mize K
    Drugs; 2009 Jun; 69(9):1205-16. PubMed ID: 19537837
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of baseline symptom burden on treatment response in COPD.
    Martinez FJ; Abrahams RA; Ferguson GT; Bjermer L; Grönke L; Voß F; Singh D
    Int J Chron Obstruct Pulmon Dis; 2019; 14():181-194. PubMed ID: 30655665
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Erratum.
    Mult Scler; 2016 Oct; 22(12):NP9-NP11. PubMed ID: 26041800
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First-Line Treatment with Tiotropium/Olodaterol Improves Physical Activity in Patients with Treatment-Naïve Chronic Obstructive Pulmonary Disease.
    Takahashi K; Uchida M; Kato G; Takamori A; Kinoshita T; Yoshida M; Tajiri R; Kojima K; Inoue H; Kobayashi H; Sadamatsu H; Tashiro H; Tanaka M; Hayashi S; Kawaguchi A; Kimura S; Sueoka-Aragane N; Kawayama T;
    Int J Chron Obstruct Pulmon Dis; 2020; 15():2115-2126. PubMed ID: 32982204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.